Navigation Links
Gen-Probe to Consolidate Industrial Assets Into New, Independent Company
Date:9/14/2009

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that it is spinning off its industrial testing assets into a new, independent company focused on developing rapid, highly accurate molecular assays for biopharmaceutical production, water and food safety testing, and other applications.

Gen-Probe initially will own 19.9% of the new company, Roka Bioscience, Inc. Affiliates of leading private equity firms OrbiMed Advisors, TPG (TPG Biotechnology) and New Enterprise Associates have agreed to provide Roka up to $37.2 million in aggregate equity funding to complete development of several industrial assays and Gen-Probe's Closed Unit Dose Assay (CUDA) system, a fully integrated, portable testing instrument that can deliver highly accurate molecular results in approximately one hour.

"We believe establishing a highly focused, standalone company is the best way to maximize the considerable long-term potential of our molecular technologies in industrial markets," said Carl Hull, Gen-Probe's president and chief executive officer (CEO). "Our ownership position enables us to participate in Roka's long-term success, while allowing us to concentrate Gen-Probe's internal resources and core competencies on clinical opportunities in infectious disease testing, blood screening, transplant diagnostics and oncology."

Eighteen former Gen-Probe employees with expertise in industrial fields have joined Roka, which will begin operating as an independent company immediately. Gen-Probe also will contribute to Roka its CUDA system, other industrial assets, and the right to use certain of its technologies and related know-how in industrial markets. In addition to biopharmaceutical production and water
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
2. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
5. Carl Hull Named President and Chief Operating Officer of Gen-Probe
6. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
7. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
8. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
9. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
10. Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference
11. Lucy Shapiro, Ph.D., Elected to Gen-Probe Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Two new members were elected to the University ... Shareholders Meeting on June 13: Kerry R. Benson, Managing ... and Stephen T. Zarrilli, President and CEO of Safeguard ... Michael A. DiPiano, Managing General Partner of New Spring ... Esq., of Duane Morris LLP, as Director Emeritus. , ...
(Date:7/22/2014)... LANSING, Mich., July 22, 2014  Neogen Corporation (NASDAQ: ... its 2014 fiscal year, which ended May 31, increased ... net income was $28,158,000, compared to the prior year,s ... 30, 2013, earnings per share in the current year ... revenues and net income for the 2014 fiscal year ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 ... di BGI, la maggiore organizzazione di genomica del mondo, ... di sequenziamento dell,intero esoma umano con base la piattaforma ... Complete Genomics, molto apprezzata nel settore per essere in ... 99.999% di precisione e una rilevazione altamente sensibile di ...
(Date:7/22/2014)... SHENZHEN, China , July 22, ... (BGI Tech), a subsidiary of BGI, the world,s ... of a new human whole exome sequencing service ... offered service includes in-depth bioinformatics analysis and SNP ... December 31, 2014. Complete Genomics, ...
Breaking Biology Technology:Two New Members Elected to University City Science Center Board of Directors 2Two New Members Elected to University City Science Center Board of Directors 3Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3
... Pafuramidine on Clinical Hold ... Schedule Zensana(TM) ... N.J., Dec. 28 Par,Pharmaceutical Companies, Inc. (NYSE: ... the,development status of its three, in-licensed, proprietary pipeline,products: ...
... ... merger, SOUTH SAN FRANCISCO, Calif., Dec. ... approved the proposed reverse split of its common stock by,a margin of nearly ... VaxGen to reverse split its stock in a ratio of 4,5, or 6 ...
... Program: Discriminating Real Science from Faux Science, ... recent meeting of,the Arizona Pain Society, Dominion Diagnostics ... of Urine Drug Testing:,Which Test, Which Patient and ... Robert Barkin, Pharm.D, MBA, FCP, DAAPM. Dr.,Barkin is ...
Cached Biology Technology:Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 2Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 3Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 4Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 5VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal 2VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal 3VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal 4Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics 2
(Date:7/21/2014)... there are reasons mammoths and mastodons could have been ... research from the University of Cincinnati, the famously fuzzy ... before it was trendy at the end of ... Crowley, an assistant professor of geology and anthropology, shows ... likely were year-round residents and not nomadic migrants as ...
(Date:7/21/2014)... to conserve water and save on your utility bill? ... published in the current issue of the journal ... The Most Effective Actions U.S. Households Can Take to ... use substantially by simple actions such as installing more ... While the suggestions may be familiar, the researchers are ...
(Date:7/21/2014)... Diego School of Medicine-led study suggests that parents of ... health consequences of childhood weight gain or the importance ... a healthy weight. , The study is published online ... and Dietetics . , "Parents have a hard time ... lead author Kyung Rhee, MD, and an assistant adjunct ...
Breaking Biology News(10 mins):Mammoth and mastodon behavior was less roam, more stay at home 2Mammoth and mastodon behavior was less roam, more stay at home 3Researchers provide guide to household water conservation 2Researchers provide guide to household water conservation 3Parents rank their obese children as 'very healthy' 2
... release is available in German . , ... by the Alfred Wegener Institute for Polar and Marine ... for the first time. Polarstern left the port of ... southern course and is located right in the Northwest ...
... the Wildlife Conservation Society, Smithsonian Tropical Research Institute, National ... a new species of fisha grouper that reaches more ... 1,000 pounds. This newly discovered species can be found ... Was the massive fish hiding among the ...
... New phase 2 data published today in The ... demonstrates activity in nonsense-mutation cystic fibrosis (CF). The ... significant improvements in the chloride channel function of patients ... the Hadassah Hebrew University Hospital in Jerusalem, Israel and ...
Cached Biology News:RV Polarstern on its way to East Siberian Sea 2RV Polarstern on its way to East Siberian Sea 3Genetics reveals big fish that almost got away 2PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 2PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 3
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Biology Products: